# Contents

**Highlights of This Issue** 3103

<table>
<thead>
<tr>
<th>SPOTLIGHT ON MOLECULAR PROFILING</th>
<th>3105</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genome-Wide mRNA and microRNA Profiling of the NCI 60 Cell-Line Screen and Comparison of FdUMP[10] with Fluorouracil, Flururidine, and Topoisomerase 1 Poisons</td>
<td>3164</td>
</tr>
<tr>
<td>William H. Gmeiner, William C. Reinhold, and Yves Pommier</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>REVIEWS</th>
<th>3115</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breaking through a Plateau in Renal Cell Carcinoma Therapeutics: Development and Incorporation of Biomarkers</td>
<td>3175</td>
</tr>
<tr>
<td>Sumanta Kumar Pal, Marcin Kortylewski, Hua Yu, and Robert A. Figlin</td>
<td></td>
</tr>
<tr>
<td>Resistance May Not Be Futile: microRNA Biomarkers for Chemoresistance and Potential Therapeutics</td>
<td>3186</td>
</tr>
<tr>
<td>Kristi E. Allen and Glen J. Weiss</td>
<td></td>
</tr>
<tr>
<td>Proof of Concept: Network and Systems Biology Approaches Aid in the Discovery of Potent Anticancer Drug Combinations</td>
<td>3200</td>
</tr>
<tr>
<td>Asfar S. Azmi, Zhiwei Wang, Philip A. Philip, Ramzi M. Mohammad, and Fazlul H. Sarkar</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>THERAPEUTIC DISCOVERY</th>
<th>3210</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Quassinoid Derivative NBT-272 Targets Both the AKT and ERK Signaling Pathways in Embryonal Tumors</td>
<td>3250</td>
</tr>
<tr>
<td>Deborah Castelletti, Giulio Fiaschetti, Valeria Di Dato, Urs Ziegler, Candy Kumps, Kateleen De Preter, Massimo Zollo, Frank Spelman, Tarok Shalaby, Daniela De Martino, Thorsten Berg, Angelika Eggert, Alexandre Arcaro, and Michael A. Grotzer</td>
<td></td>
</tr>
</tbody>
</table>

**Modulation of 4E-BP1 Function as a Critical Determinant of Enzastaurin-Induced Apoptosis**
- Chad A. Dumstorf, Bruce W. Konicek, Ann M. McNulty, Stephen H. Parsons, Luc Furic, Nahum Sonenberg, and Jeremy R. Graff

**Antagonism of Cytotoxic Chemotherapy in Neuroblastoma Cell Lines by 13-cis-Retinoic Acid Is Mediated by the Antiapoptotic Bcl-2 Family Proteins**
- Michael D. Hadjidaniel and C. Patrick Reynolds

**Monensin Is a Potent Inducer of Oxidative Stress and Inhibitor of Androgen Signaling Leading to Apoptosis in Prostate Cancer Cells**
- Kirsi Ketola, Paula Vainio, Vidal Fey, Olli Kallioniemi, and Kristiina Iljin

**Targeting Aldehyde Dehydrogenase Cancer Stem Cells in Ovarian Cancer**

**Combined Inhibition of Notch Signaling and Bcl-2/Bcl-xL Results in Synergistic Antimyeloma Effect**
- Ming Li, Feng Chen, Nicholas Clifton, Daniel M. Sullivan, William S. Dalton, Dmitry I. Gabrilovich, and Yulia Nefedova

**The Histone Deacetylase Inhibitor, Vorinostat, Reduces Tumor Growth at the Metastatic Bone Site and Associated Osteolysis, but Promotes Normal Bone Loss**
- Jitesh Pratap, Jacqueline Akech, John J. Wixted, Gabriela Szabo, Sadiq Hussain, Meghan E. McGee-Lawrence, Xiaodong Li, Krystin Bedard, Robinder J. Dhillion, Andre J. van Wijnen, Janet L. Stein, Gary S. Stein, Jennifer J. Westendorf, and Jane B. Lian

---

*Downloaded from mct.aacrjournals.org on August 6, 2021. © 2010 American Association for Cancer Research.*
Peroxisome Proliferator-Activated Receptor-γ Activation Inhibits Tumor Metastasis by Antagonizing Smad3-Mediated Epithelial-Mesenchymal Transition

Ajaya Kumar Reka, Himabindu Kura-pati, Venkata R. Narala, Guido Bommer, Jun Chen, Theodore J. Standiford, and Venkateshwar G. Keshamouni

Combined Treatment with Silibinin and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Overcomes Drug Resistance Caused by T790M Mutation

Jin Kyung Rho, Yun Jung Choi, Byung-Suk Jeon, Su Jin Choi, Gi Jeong Cheon, Sang-Keun Woo, Hye-Ryoun Kim, Cheol Hyeon Kim, Chang-Min Choi, and Jae Cheol Lee

Antiangiogenic Activity of a Neutralizing Human Single-Chain Antibody Fragment against Fibroblast Growth Factor Receptor 1

Roberto Ronca, Patrizia Benzioni, Daria Leali, Chiara Urbinati, Mirella Belleri, Michela Corsini, Patrizia Alesi, Daniela Coltrini, Stefano Calza, Marco Presta, and Patrizia Dell’Era

MS-275 Sensitizes TRAIL-Resistant Breast Cancer Cells, Inhibits Angiogenesis and Metastasis, and Reverses Epithelial-Mesenchymal Transition In vivo

Rakesh K. Srivastava, Roberti Bai, Mary J. Kennett, Boo-Hyon Kang, Frank J. Gonzalez, and Jeffrey M. Peters

Detection of Tumor Response to a Vascular Disrupting Agent by Hyperpolarized 13C Magnetic Resonance Spectroscopy

Sarah E. Bohndiek, Mikko I. Kettunen, De-en Hu, Timothy H. Witney, Brett W.C. Kennedy, Ferdia A. Gallagher, and Kevin M. Brindle

Combination of Vorinostat and Flavopiridol Is Selectively Cytotoxic to Multidrug-Resistant Neuroblastoma Cell Lines with Mutant TP53

Jen-Ming Huang, Michael A. Sheard, Lingyun Ji, Richard Sposto, and Nino Keshelava

Inhibition of Constitutive Activation of STAT3 by Curcubritin-1 (JSI-124) Sensitized Human B-Leukemia Cells to Apoptosis

Ganchimeg Ishdorj, James B. Johnston, and Spencer B. Gibson

Cytochrome P450 1B1 Gene Polymorphisms as Predictors of Anticancer Drug Activity: Studies with In vitro Models

Audrey Laroche-Clary, Valérie Le Morvan, Takao Yamori, and Jacques Robert

A Synergistic Interaction between Lapatinib and Chemotherapy Agents in a Panel of Cell Lines Is Due to the Inhibition of the Efflux Pump BCRP

Jackie Perry, Essam Ghazaly, Christiana Kitromilidou, Eva H. McGrowder, Simon Joel, and Thomas Powles

Rb–Raf-1 Interaction Disruptor RRD-251 Induces Apoptosis in Metastatic Melanoma Cells and Synergizes with Dacarbazine

Sandeep Singh, Rebecca Davis, Vignesh Alamanda, Roberta Pireddu, Daniel Pernazza, Said Sebti, Nicholas Lawrence, and Srikumar Chellappan

Cyclin G–Associated Kinase Is Necessary for Osteosarcoma Cell Proliferation and Receptor Trafficking

Michiro Susa, Edwin Choy, Xianzhe Liu, Joseph Schwab, Francis J. Hornick, Henry Mankin, and Zhenfeng Duan

Identification of Predictive Markers of Response to the MEKfs1/2 Inhibitor Selumetinib (AZD6244) in K-ras–Mutated Colorectal Cancer

John J. Tentler, Sujatha Nallapareddy, Aik Choon Tan, Anna Spreafico, Todd M. Pitts, M. Pia Morelli, Heather M. Selby, Maria I. Kachaeva, Sara A. Flanigan, Gillian N. Kulikowski, Stephen Leong, John J. Arcaroli, Wells A. Messersmith, and S. Gail Eckhardt

PRECLINICAL DEVELOPMENT
Contrasting Effects of Nutlin-3 on TRAIL- and Docetaxel-Induced Apoptosis Due to Upregulation of TRAIL-R2 and Mcl-1 in Human Melanoma Cells
Hsin-Yi Tseng, Chen Chen Jiang, Amanda Croft, Kwang Hong Tay, Rick Francis Thorne, Fan Yang, Hao Liu, Peter Hersey, and Xu Dong Zhang

Nakiterpiosin Targets Tubulin and Triggers Mitotic Catastrophe in Human Cancer Cells
Jen-Hsuan Wei and Joachim Seemann

AZ960, a Novel Jak2 Inhibitor, Induces Growth Arrest and Apoptosis in Adult T-Cell Leukemia Cells
Jing Yang, Takayuki Ikezoe, Chie Nishioka, Mutsuo Furihata, and Akihito Yokoyama

Specific Alterations of MicroRNA Transcriptome and Global Network Structure in Colorectal Carcinoma after Cetuximab Treatment
Marco Ragusa, Alessandra Majorana, Luisa Statello, Marco Maugeri, Loredana Salito, Davide Barbagallo, Maria Rosa Guglielmino, Laura R. Duro, Rosario Angelica, Rosario Caltabiano, Antonio Biondi, Maria Di Vita, Giuseppe Privitera, Marina Scala, Alessandro Cappellani, Enrico Vasquez, Salvatore Lanzafame, Francesco Basile, Cinzia Di Pietro, and Michele Purrello

 AZ960, a Novel Jak2 Inhibitor, Induces Growth Arrest and Apoptosis in Adult T-Cell Leukemia Cells

Specific Alterations of MicroRNA Transcriptome and Global Network Structure in Colorectal Carcinoma after Cetuximab Treatment

About the Cover
Aldehyde dehydrogenase-1A1 (ALDH1A1) is heterogeneously expressed in multiple tumors. Cells with ALDH1A1 activity have been shown to have increased tumorigenicity, differentiation capacity, and chemoresistance. To confirm that the spotty heterogeneous expression of ALDH1A1 was not being visualized in tumor-infiltrating macrophages, frozen patient samples were subjected to dual immunohistochemistry against ALDH1A1 (DAB/brown) and CD68 (a pan-macrophage marker, Ferangi Blue), where distinct populations are noted. Landen and colleagues show that increased ALDH1A1 expression was associated with poor survival and is a viable target for therapy in preclinical models of ovarian cancer. For details, see article by Landen and colleagues on page 3186.
Molecular Cancer Therapeutics

9 (12)

Mol Cancer Ther 2010;9:3103-3426.

Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/9/12

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link:
http://mct.aacrjournals.org/content/9/12.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.